Correspondence 0001193125-23-234397 from Tourmaline Bio, Inc. (TRML) (CIK 0001827506)
Tourmaline Bio, Inc. (TRML) (CIK 0001827506)
Date: Sept. 13, 2023 · CIK: 0001827506 · Accession: 0001193125-23-234397
AI Filing Summary & Sentiment
File numbers found in text: 333-273335
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance Attention: Requested Date: September 14, 2023 Requested Time: 5:30 p.m. Eastern Time
Dear Ms. Gama, Mr. Buchmillar, Ms. Torney and Mr. Gordon:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Talaris Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 14, 2023, at 5:30 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Sarah Ashfaq at (212) 459-7238. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Sarah Ashfaq, by email to sashfaq@goodwinlaw.com.
If you have any questions regarding this request, please contact Sarah Ashfaq of Goodwin Procter LLP at (212) 459-7238.
Sincerely,
Talaris Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Talaris Therapeutics, Inc. 93 Worcester St. Wellesley, MA 02481 September 13, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street NE Washington, D.C. 20549-3628 Attention: Ms. Doris Stacey Gama Mr. Tim Buchmillar Ms. Christine Torney Mr. Daniel Gordon Re: Talaris Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-4 File No. 333-273335 Requested Date: September 14, 2023 Requested Time: 5:30 p.m. Eastern Time Dear Ms. Gama, Mr. Buchmillar, Ms. Torney and Mr. Gordon: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Talaris Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 14, 2023, at 5:30 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Sarah Ashfaq at (212) 459-7238. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Sarah Ashfaq, by email to sashfaq@goodwinlaw.com. If you have any questions regarding this request, please contact Sarah Ashfaq of Goodwin Procter LLP at (212) 459-7238. Sincerely, Talaris Therapeutics, Inc. /s/ Mary Kay Fenton Mary Kay Fenton Chief Financial Officer and Interim Chief Executive Officer and President cc: Sarah Ashfaq, Goodwin Procter LLP John T. Haggerty, Goodwin Procter LLP Richard A. Hoffman, Goodwin Procter LLP Tevia K. Pollard, Goodwin Procter LLP